TABLE 2.

Use of fluconazole to predict susceptibility patterns of voriconazole, using 13,338 clinical isolates of Candida spp. from the Global Antifungal Surveillance Program

Species (no. of isolates tested)	Fluconazole susceptibility categorya	No. (%) in voriconazole categoryb:
		S (≤1 μg/ml)	SDD (2 μg/ml)	R (≥4 μg/ml)
All Candida (13,338)	S	12,087 (90.6)	0 (0.0)	0 (0.0)
	SDD	836 (6.3)	16 (0.1)	3 (0.1)
	R	192 (1.4)	94 (0.7)	110 (0.8)
All Candida minus C. krusei (13,026)	S	12,078 (92.7)	0 (0.0)	0 (0.0)
	SDD	659 (5.1)	16 (0.1)	3 (0.1)
	R	68 (0.5)	93 (0.7)	109 (0.8)
C. albicans (7,725)	S	7,638 (98.9)	0. (0.0)	0 (0.0)
	SDD	37 (0.5)	1 (0.01)	0 (0.0)
	R	25 (0.3)	9 (0.1)	15 (0.19)
C. glabrata (1,966)	S	1,217 (61.9)	0 (0.0)	0 (0.0)
	SDD	557 (28.3)	10 (0.5)	1 (0.1)
	R	30 (1.5)	79 (4.0)	72 (3.7)
C. parapsilosis (1,623)	S	1,577 (97.2)	0. (0.0)	0 (0.0)
	SDD	36 (2.2)	2 (0.1)	0 (0.0)
	R	5 (0.3)	2 (0.1)	1 (0.1)
C. tropicalis (1,253)	S	1,223 (97.6)	0 (0.0)	0 (0.0)
	SDD	5 (0.4)	2 (0.2)	2 (0.2)
	R	2 (0.2)	1 (0.1)	16 (1.3)
C. krusei (312)	S	9 (2.8)	0 (0.0)	0 (0.0)
	SDD	177 (56.7)	0 (0.0)	0 (0.0)
	R	124 (39.7)	1 (0.4)	1 (0.4)
C. lusitaniae (134)	S	130 (97.0)	0 (0.0)	0 (0.0)
	SDD	2 (1.4)	1 (0.8)	0 (0.0)
	R	1 (0.8)	0 (0.0)	0 (0.0)
C. dubliniensis (103)	S	94 (91.3)	0 (0.0)	0 (0.0)
	SDD	6 (5.8)	0 (0.0)	0 (0.0)
	R	1 (1.0)	0 (0.0)	2 (1.9)
C. guilliermondii (92)	S	83 (90.2)	0 (0.0)	0 (0.0)
	SDD	6 (6.5)	0 (0.0)	0 (0.0)
	R	0 (0.0)	2 (2.2)	1 (1.1)
C. pellliculosa (34)	S	34 (100)	0 (0.0)	0 (0.0)
	SDD	0 (0.0)	0 (0.0)	0 (0.0)
	R	0 (0.0)	0 (0.0)	0 (0.0)
C. kefyr (33)	S	33 (100)	0 (0.0)	0 (0.0)
	SDD	0 (0.0)	0 (0.0)	0 (0.0)
	R	0 (0.0)	0 (0.0)	0 (0.0)
C. famata (19)	S	14 (73.7)	0 (0.0)	0 (0.0)
	SDD	5 (26.3)	0 (0.0)	0 (0.0)
	R	0 (0.0)	0 (0.0)	0 (0.0)
C. rugosa (19)	S	19 (100)	0 (0.0)	0 (0.0)
	SDD	0 (0.0)	0 (0.0)	0 (0.0)
	R	0 (0.0)	0 (0.0)	0 (0.0)

^aS, MIC of ≤8 μg/ml; SDD, MIC of 16 to 32 μg/ml; R, MIC of ≥64 μg/ml.

^bVoriconazole susceptibility categories are as described by Pfaller et al. (30).